Geleneksel Kemoterapötik Kombinasyonların (FOLFOX, FOLFIRI) Kolon Kanseri Hücreleri Üzerindeki Büyüme-Engelleyici Etkileri: Bir in vitro Çalışma

Yıl 2024, Cilt: 9 Sayı: 4, 349 - 356

Aslı Yıldırım Kocaman , Seçil Erden Tayhan

https://doi.org/10.26453/otjhs.1538781

Öz

Amaç: Yaygın olarak kullanılan kemoterapötik kombinasyonlar olan folinik asit, 5-florourasil ve oksaliplatin (FOLFOX) ile folinik asit, 5-florourasil ve irinotekanın (FOLFIRI) kolon kanseri hücreleri (HT29 ve CaCo-2 hücreleri) üzerindeki in vitro büyümeyi inhibe edici etkilerini karşılaştırmak.
Materyal ve Metot: FOLFOX ve FOLFIRI kombinasyonlarının farklı konsantrasyonlarıyla tedavi edilen HT29 ve CaCo-2 hücrelerinin canlılığı MTT (3-(4,5-dimetiltiazolil-2)-2,5-difeniltetrazolium bromür) testi kullanılarak değerlendirildi.
Bulgular: FOLFOX ve FOLFIRI kombinasyonları kolon kanseri hücre hatları üzerinde farklı etkiler gösterdi, HT29 hücreleri duyarlılık gösterirken, CaCo-2 hücreleri bu tedavilere direnç gösterdi.
Sonuç: Bu ön çalışmanın sonuçları, kolon kanseri için etkili ve hedefli klinik tedavi stratejilerinin geliştirilmesine katkıda bulunacaktır.

Anahtar Kelimeler

Antiproliferatif etki, FOLFIRI, FOLFOX, ilaç kombinasyonu, kolon kanseri

Etik Beyan

This research utilized commercially available cell lines. As such, no ethics committee approval was necessary for this study. The research adhered to international declarations and guidelines.

Growth-Inhibitory Effects of Traditional Chemotherapeutic Combinations (FOLFOX, FOLFIRI) on Colon Cancer Cells: An in vitro Study

Öz

Objective: To compare the in vitro growth-inhibitory effects of the commonly used chemotherapeutic combinations folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX) and folinic acid, 5-fluorouracil, and irinotecan (FOLFIRI) on colon cancer cells (HT29 and CaCo-2 cells).
Materials and Methods: The viability of HT29 and CaCo-2 cells treated with different concentrations of the FOLFOX and FOLFIRI combinations was evaluated using the MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay.
Results: FOLFOX and FOLFIRI combinations exhibited varying effects on the colon cancer cell lines, with HT29 cells showing sensitivity, while CaCo-2 cells demonstrated resistance to these treatments.
Conclusions: The results of this preliminary study will contribute to the development of effective and targeted clinical treatment strategies for colon cancer.

Anahtar Kelimeler

Colon cancer, drug combination, FOLFOX, FOLFIRI, growth-inhibitory effect

Etik Beyan

This research utilized commercially available cell lines. As such, no ethics committee approval was necessary for this study. The research adhered to international declarations and guidelines.

Kaynakça

• Gach-Janczak K, Drogosz-Stachowicz J, Janecka A, Wtorek K, Mirowski M. Historical Perspective and Current Trends in Anticancer Drug Development. Cancers. 2024;16(10):1878. doi:10.3390/CANCERS16101878
• Azwar S, Seow HF, Abdullah M, Jabar MF, Mohtarrudin N. Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment. Biology. 2021;10(9):854. doi:10.3390/BIOLOGY10090854
• Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1):1-30. doi:10.1038/s41392-020-0116-z
• Liu X, Ou K, Ma X, et al. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. BMC Cancer. 2022;22(1):807. doi:10.1186/S12885-022-09889-3
• Ashique S, Bhowmick M, Pal R, et al. Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success. Adv Cancer Biol - Metastasis. 2024;10:100114. doi:10.1016/J.ADCANC.2024.100114
• Narayan S, Raza A, Mahmud I, et al. Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A. iScience. 2022;25(7). doi:10.1016/J.ISCI.2022.104518
• Sethy C, Kundu CN. 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomed Pharmacother. 2021;137: 111285. doi:10.1016/J.BIOPHA.2021.111285
• Glimelius B, Stintzing S, Marshall J, Yoshino T, de Gramont A. Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treat Rev. 2021;98:102218. doi:10.1016/J.CTRV.2021.102218
• Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther. 2020;206:107447. doi:10.1016/J.PHARMTHERA.2019.107447
• Chai Y, Liu JL, Zhang S, et al. The effective combination therapies with irinotecan for colorectal cancer. Front Pharmacol. 2024;15:1356708. doi:10.3389/FPHAR.2024.1356708/BIBTEX
• Kumar S, Sherman MY. Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us. Int J Mol Sci. 2023;24(8):7233. doi:10.3390/IJMS24087233
• Amniouel S, Jafri MS. High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data. Front Physiol. 2023;14:1272206. doi:10.3389/FPHYS.2023.1272206
• Bilgin S, Erden Tayhan S, Yıldırım A, Koç E. Investigation of the effects of isoeugenol-based phenolic compounds on migration and proliferation of HT29 colon cancer cells at cellular and molecular level. Bioorg Chem. 2023;130:106230. doi:10.1016/J.BIOORG.2022.106230
• Galateanu B, Hudita A, Negrei C, et al. Impact of multicellular tumor spheroids as an in vivo-like tumor model on anticancer drug response. Int J Oncol. 2016;48(6):2295. doi:10.3892/IJO.2016.3467
• Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669-685. doi:10.1001/JAMA.2021.0106
• Pathak PS, Chan G, Deming DA, Chee CE. State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation. https://doi.org/101200/EDBK_438466. 2024;44(3). doi:10.1200/EDBK_438466
• Wanes D, Naim HY, Dengler F. Proliferation and Differentiation of Intestinal Caco-2 Cells Are Maintained in Culture with Human Platelet Lysate Instead of Fetal Calf Serum. Cells. 2021;10(11):3038. doi:10.3390/CELLS10113038
• Zoetemelk M, Ramzy GM, Rausch M, Nowak-Sliwinska P. Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. Molecules. 2020;25(11):2614. doi:10.3390/MOLECULES25112614
• Machover D, Almohamad W, Castagné V, Desterke C, Gomez L, Goldschmidt E. Treatment of patients with carcinomas in advanced stages with 5-fluorouracil, folinic acid and pyridoxine in tandem. Sci Rep. 2024;14(1):12054. doi:10.1038/S41598-024-62860-Z
• Budithi A, Su S, Kirshtein A, Shahriyari L. Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. Cancers. 2021;13(11):2632. doi:10.3390/CANCERS13112632
• Gagnon M, Zihler Berner A, Chervet N, Chassard C, Lacroix C. Comparison of the Caco-2, HT-29 and the mucus-secreting HT29-MTX intestinal cell models to investigate Salmonella adhesion and invasion. J Microbiol Methods. 2013;94(3):274-279. doi:10.1016/J.MIMET.2013.06.027
• Gmeiner WH. Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment. Cancers (Basel). 2024;16(5):1029. doi:10.3390/CANCERS16051029
• Gu J, Li Z, Zhou J, Sun Z, Bai C. Response prediction to oxaliplatin plus 5-fluorouracil chemotherapy in patients with colorectal cancer using a four-protein immunohistochemical model. Oncology Letters. 2019;18(2):2091-2101. doi:10.3892/OL.2019.10474
• Lenaerts K, Bouwman FK, Lamers WH, Renes J, Mariman EC. Comparative proteomic analysis of cell lines and scrapings of the human intestinal epithelium. BMC Genomics. 2007;8:1-14. doi:10.1186/1471-2164-8-91
• Haddad MJ, Sztupecki W, Delayre-Orthez C, et al. Complexification of In Vitro Models of Intestinal Barriers, A True Challenge for a More Accurate Alternative Approach. International Journal of Molecular Sciences. 2023;24(4):3595. doi:10.3390/IJMS24043595
• Slaninová V, Heron-Milhavet L, Robin M, et al. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells. BMC Cancer. 2024;24(1):1-18. doi:10.1186/S12885-024-12316-4/FIGURES/6
• Cerbone A, Toaldo C, Minelli R, et al. Rosiglitazone and AS601245 Decrease Cell Adhesion and Migration through Modulation of Specific Gene Expression in Human Colon Cancer Cells. PLoS One. 2012;7(6):e40149. doi:10.1371/JOURNAL.PONE.0040149
• Ramzy GM, Boschung L, Koessler T, et al. FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells. Cancers. 2022;14(19):4812. doi:10.3390/CANCERS14194812